Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COSINR Study: Ipilimumab, Nivolumab, and SBRT in Stage IV NSCLC
NCT03223155Phase 1Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Sep 2017
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nivolumab and ipilimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University of Chicago. Primary endpoint: Number of serious adverse events up to 4 years. Started Sep 2017; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03223155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03223155.